Advancement in mRNA and LNP technology for next generation therapeutics development
GenScript is advancing mRNA and LNP technologies to address challenges in stability, delivery, and immune modulation. Innovations in mRNA design and LNP engineering enhance T cell targeting, liver cell prime editing, and antibody generation in murine models. These breakthroughs support next-generation therapies for cancer, genetic, and complex diseases. GenScript seeks collaborations to accelerate mRNA-LNP platform development.

Enzymatic Assembly of Ultra-long gRNA at Gram Scale
The demand for ultra-long oligonucleotides (>150nt) is growing due to advanced editing technologies like prime editing. However, the iterative synthesis cycle leads to exponential buildup of impurities and side products with length increase. To address this, a fragment-based assembly approach should be used to minimize impurity aggregation for ultra-long gRNAs.
GenScript has adapted its synthetic platform to facilitate enzymatic assembly of ultra-long gRNAs (over 200nts). Through optimization of enzymes, reaction conditions, and fragment dissecting strategies, ultra-long gRNAs of 241nt have been successfully assembled. Comprehensive comparisons of quality attributes (UPLC, MS, NGS, and eff%) demonstrate the superiority of enzymatically assembled ultra-long gRNAs over those generated from intact chemical synthesis.
Furthermore, the manufacturing process has been enhanced to produce ultra-long gRNAs at gram scale. This advancement enables GenScript to offer a superior solution for manufacturing ultra-long gRNAs to support from research all the way up to the clinical phase.